Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Myotonic diseases since Asmus Julius Thomas Thomsen (1815–1896) and Peter Emil Becker (1908–2000)

View through CrossRef
Julius Thomsen first published his account of myotonia (an unusual muscle stiffness disorder) in himself and his family in 1876. By November 1971, Peter Becker was already famous for his eponymous Becker muscular dystrophy when he came to the Second International Congress on Muscle Diseases, in Perth. There, he presented an extensive study of myotonia, recognising a recessively inherited disease (now known as Becker’s recessive generalised myotonia), distinct from Thomsen’s myotonia congenita and clearly distinguishable from Steinert’s myotonic dystrophy, both dominantly inherited. Peter Becker, Shirley Bryant, Reinhardt Rüdel and Allan Bretag all met in Perth, with mutual interests in myotonia. They subsequently maintained contact while Bretag undertook research in Germany in 1972–1973 and 1977. Later, in 1978, Bretag worked with Bryant’s myotonic goats in Cincinnati. His research on Thomsen’s and Becker’s myotonias has since progressed to confirmation of Bryant’s chloride hypothesis through a molecular genetic study of the muscle chloride channel, CLC -1. This has culminated in several collaborative papers with German colleagues and, finally, in a mechanistic description of how the CLC -1 channel is gated.
Title: Myotonic diseases since Asmus Julius Thomas Thomsen (1815–1896) and Peter Emil Becker (1908–2000)
Description:
Julius Thomsen first published his account of myotonia (an unusual muscle stiffness disorder) in himself and his family in 1876.
By November 1971, Peter Becker was already famous for his eponymous Becker muscular dystrophy when he came to the Second International Congress on Muscle Diseases, in Perth.
There, he presented an extensive study of myotonia, recognising a recessively inherited disease (now known as Becker’s recessive generalised myotonia), distinct from Thomsen’s myotonia congenita and clearly distinguishable from Steinert’s myotonic dystrophy, both dominantly inherited.
Peter Becker, Shirley Bryant, Reinhardt Rüdel and Allan Bretag all met in Perth, with mutual interests in myotonia.
They subsequently maintained contact while Bretag undertook research in Germany in 1972–1973 and 1977.
Later, in 1978, Bretag worked with Bryant’s myotonic goats in Cincinnati.
His research on Thomsen’s and Becker’s myotonias has since progressed to confirmation of Bryant’s chloride hypothesis through a molecular genetic study of the muscle chloride channel, CLC -1.
This has culminated in several collaborative papers with German colleagues and, finally, in a mechanistic description of how the CLC -1 channel is gated.

Related Results

Battling the un-dead: the status of the Diptera genus-group names originally proposed in Johann Wilhelm Meigen’s 1800 pamphlet
Battling the un-dead: the status of the Diptera genus-group names originally proposed in Johann Wilhelm Meigen’s 1800 pamphlet
The work of Meigen 1800 was suppressed by the ICZN Commission in 1963 for the purposes of zoological nomenclature. The work as such is still to be treated as having been published ...
OR-1896 increases force of contraction in the isolated human atrium
OR-1896 increases force of contraction in the isolated human atrium
Abstract OR-1896 ((R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl) phenyl)-acetamide) is the main active metabolite of levosimendan. However, nobody has reported ...
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
This randomized clinical trial explores whether hormone intensification at start of androgen deprivation therapy alters selection of androgen receptor (AR) gene alterations within ...
Dr. Peter Emil Becker and the Third Reich: Correspondence
Dr. Peter Emil Becker and the Third Reich: Correspondence
ABSTRACT Peter Emil Becker was a German neurologist who is remembered for his studies of muscular dystrophies. Becker muscular dystrophy and ...
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on...
Blunt Chest Trauma and Chylothorax: A Systematic Review
Blunt Chest Trauma and Chylothorax: A Systematic Review
Abstract Introduction: Although traumatic chylothorax is predominantly associated with penetrating injuries, instances following blunt trauma, as a rare and challenging condition, ...
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Abstract The ODYSSEY OUTCOMES trial, comprising over 47 000 patient-years of placebo-controlled observation, demonstrated important reductions in the risk of recurre...
Abstract 5171: Development of preclinical models of NTRK fusion-driven cancers
Abstract 5171: Development of preclinical models of NTRK fusion-driven cancers
Abstract Introduction: Oncogenic fusions involving the neurotrophic receptor tyrosine kinase genes, NTRK1, NTRK2, or NTRK3 are d...

Back to Top